Literature DB >> 29259459

Assisted reproductive technology in Japan: a summary report of 1992-2014 by the Ethics Committee, Japan Society of Obstetrics and Gynecology.

Minoru Irahara1, Akira Kuwahara1, Takeshi Iwasa1, Tomonori Ishikawa2, Osamu Ishihara3, Koji Kugu4, Rintaro Sawa5,6, Kouji Banno7, Hidekazu Saito8.   

Abstract

Aim: The Japan Society of Obstetrics and Gynecology implemented a registry report system for the clinical practice of assisted reproductive technology in 1986. The aggregated results from 1992 to 2014 are reported herein. Methods and
Results: The total number of registered treatments was 393 745 cycles, of which 66 550 were pregnancy cycles and 46 008 were cycles with a live birth. Compared to the number of registered treatments in 2008, when the cycle-based registry was newly introduced, there was a 2.07-fold increase in the total number of treatments and a 2.25-fold increase in the number of cycles with a live birth. As the average age of patients who receive assisted reproductive technology has become markedly higher year by year, the most common age of those patients who received assisted reproductive technology in 2014 was 40 years.
Conclusion: The total numbers of both assisted reproductive technology treatments and assisted reproductive technology live births are likely to be higher in the future. In addition, the trend toward aging patients seems to be continuing into the future.

Entities:  

Keywords:  Japan Society of Obstetrics and Gynecology; assisted reproductive technology; in vitro fertilization; intracytoplasmic sperm injection

Year:  2017        PMID: 29259459      PMCID: PMC5661813          DOI: 10.1002/rmb2.12014

Source DB:  PubMed          Journal:  Reprod Med Biol        ISSN: 1445-5781


Introduction

The Japan Society of Obstetrics and Gynecology (JSOG) implemented a registry report system for the clinical practice of assisted reproductive technology (ART) in 1986. Starting with the report for fiscal year 1989 (The First Report),1 the JSOG continuously has reported the clinical outcomes of ART.2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 Since 2008, the JSOG has implemented an online cycle‐based registry system (individual surveys). The most recent version of the annual report is 2014 (the period from January 1 to December 31, 2014) that was published previously in Japanese.25 As Japan has been the largest contributor of ART in terms of the annual amount of practice, herewith is presented the aggregate results for Japan.

Materials and Methods

For all patients who began treatment between January 1 and December 31, 2014, data for all treatment cycles that were performed at all ART treatment facilities nationwide were entered for each treatment cycle by using the online registry system by the end of November, 2015. The contents that were investigated are shown in Tables 1 and 2.
Table 1

Cycle‐based registry form: clinical outcome of assisted reproductive technology

Patient ID number (req)Unique ID for patient
Use of governmental support system for ART (req)

Yes

No

Unknown

Woman's age at starting of therapy (req)( ) years old
Man's age at starting of therapy (req)( ) years old
Height and body weight at starting of therapy Height ( ) cm
Body weight ( ) kg
Pregnancy historyGravida ( )
Para ( )
Cause of infertility (req)

Tubal dysfunction

Endometriosis

Antisperm antibody

Male factor

Unknown

Others ( )

Oocyte cryopreservation (medical indication)

Type of controlled ovarian stimulation

Natural

CC

CC + hMG or FSH

hMG or FSH

GnRH agonist + hMG or FSH

GnRH antagonist + hMG or FSH

Others ( )

Hormone replacement cycle

Method of oocyte pick up (req)

Failed

Endovaginal ultrasonography

Laparoscopy

Use of thawed egg or embryo

Others ( )

Type of used egg or embryo (req) 1. Fresh egg or embryo 2. Frozen thawed embryo 3. Frozen thawed egg ※ If check (2. Frozen thawed embryo), input the registration number at oocyte pick up ( )
Therapeutic method (req)

IVF–ET

GIFT

ICSI

IVF‐ET + ICSI

Thawed embryo

Others ( )

Oocyte cryopreservation (medical indication)

Type of sperm collection

Ejaculated sperm

TESE

Others ( )

Sperm analysis ※ If check (1. Ejaculated sperm) in (Type of sperm collection), input the results of sperm analysis Concentration ( ) ×106/mL (the second decimal place) Motility ( ) %
If check (1. Fresh eggs or embryo) in (Types of used egg or embryo), input of following two items is necessary
Number of eggs retrieved( )
Number of fertilized eggs( )
If check (2. Frozen thawed embryo) in (Types of used egg or embryo), input of following item is necessary
Number of thawed embryos( )
If check (3. Frozen thawed egg) in (Types of used egg or embryo), input of following two items is necessary
Number of thawed eggs( )
Number of fertilized eggs after thawed( )
If check any of three alternatives in (Types of used egg or embryo), input of following seven items is necessary
Stage of embryo at embryo transfer

Egg (unfertilized)

Cleavage embryos

Blastocysts

ET cancellation

Others ( )

Number of egg or embryo transfers( )
Number of frozen egg or embryos( )
Assisted hatching

Yes

No

Luteal support

None

Progesterone (P)

hCG

hCG + P

Estrogen + P

Others ( )

Complications

None

Bleeding

Infection

OHSS (more than Stage II)

Others ( )

Having pregnancy or not

None

Clinical pregnancy (Evidence by ultrasound of an intrauterine sac with or without a fetal heart) (Date of embryo transfer [day/month/year])

※ If check (2. Clinical pregnancy), input the (Data items from pregnancy to delivery) form.

Undetermined

※ Reselect (1. None) or (2. Clinical pregnancy) after determined.

req, required; ART, assisted reproductive technology; CC, clomiphene citrate; hMG, human menopausal gonadotropin; FSH, follicle‐stimulating hormone; GnRH, gonadotropin‐releasing hormone; IVF–ET, in vitro fertilization–embryo transfer; GIFT, gamete intrafallopian transfer; ICSI, intracytoplasmic sperm injection; TESE, testicular sperm extraction; OHSS, ovarian hyperstimulation syndrome.

Table 2

Cycle‐based registry form: obstetric outcome of pregnancy

Number of gestational sacs (req)( )
Number of fetal heartbeat( )
Outcome of pregnancy (req)

Miscarriage

Ectopic pregnancy

Heterotopic pregnancy

Elective termination of pregnancy (reason: )

Live birth

Stillbirth

Selective reduction performed (number of fetus before reduction [ ], number of fetuses after reduction [ ])

Unknown

Number of live births※ If check (5. Live birth) or (6. Stillbirth) in (Outcome of pregnancy), input is necessary
Number ( ) (Date of delivery [day/month/year])
Style of delivery

Vaginal delivery

Cesarean delivery

Vaginal and cesarean delivery

Unknown

Obstetric complications of pregnancy

None

Yes

Unknown

req, required.

Cycle‐based registry form: clinical outcome of assisted reproductive technology Yes No Unknown Tubal dysfunction Endometriosis Antisperm antibody Male factor Unknown Others ( ) Oocyte cryopreservation (medical indication) Natural CC CC + hMG or FSH hMG or FSH GnRH agonist + hMG or FSH GnRH antagonist + hMG or FSH Others ( ) Hormone replacement cycle Failed Endovaginal ultrasonography Laparoscopy Use of thawed egg or embryo Others ( ) IVF–ET GIFT ICSI IVF‐ET + ICSI Thawed embryo Others ( ) Oocyte cryopreservation (medical indication) Ejaculated sperm TESE Others ( ) Egg (unfertilized) Cleavage embryos Blastocysts ET cancellation Others ( ) Yes No None Progesterone (P) hCG hCG + P Estrogen + P Others ( ) None Bleeding Infection OHSS (more than Stage II) Others ( ) None Clinical pregnancy (Evidence by ultrasound of an intrauterine sac with or without a fetal heart) (Date of embryo transfer [day/month/year]) ※ If check (2. Clinical pregnancy), input the (Data items from pregnancy to delivery) form. Undetermined ※ Reselect (1. None) or (2. Clinical pregnancy) after determined. req, required; ART, assisted reproductive technology; CC, clomiphene citrate; hMG, human menopausal gonadotropin; FSH, follicle‐stimulating hormone; GnRH, gonadotropin‐releasing hormone; IVF–ET, in vitro fertilization–embryo transfer; GIFT, gamete intrafallopian transfer; ICSI, intracytoplasmic sperm injection; TESE, testicular sperm extraction; OHSS, ovarian hyperstimulation syndrome. Cycle‐based registry form: obstetric outcome of pregnancy Miscarriage Ectopic pregnancy Heterotopic pregnancy Elective termination of pregnancy (reason: ) Live birth Stillbirth Selective reduction performed (number of fetus before reduction [ ], number of fetuses after reduction [ ]) Unknown Vaginal delivery Cesarean delivery Vaginal and cesarean delivery Unknown None Yes Unknown req, required.

Results and Discussion

There were 598 registered ART facilities in 2014 and the ART treatments at all of these facilities were registered. The number of facilities that actually provided ART treatment in 2014 was 574; the number of implemented cycles was zero at 24 facilities. Figure 1 shows the age distribution of the patients for all registered treatment cycles. The total number of registered treatments was 393 745 cycles, of which 66 550 were pregnancy cycles and 46 008 were cycles with a live birth. Compared to the number of registered treatments in 2008 (Figure 2), there was a 2.07‐fold increase in the total number of treatments and a 2.25‐fold increase in the number of cycles with a live birth. The age of the patients who receive ART has become markedly higher each year and the most common age of those patients who received ART in 2014 was 40 years. The trend toward an increasing patient age is thought to continue into the future. Figures 3 and 4 show the annual changes in the number of registered cycles and live births since registration began in 1992. The increases in the total number of ART treatments and ART live births are thought to continue for some time into the future. The total number of ART live births that was registered between 1992, the year in which registration began, and 2014 was 431 626.
Figure 1

Age distribution of the women who were treated with assisted reproductive technology procedures in Japan in 2014. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2014 (https://plaza.umin.ac.jp/~jsog-art/2014data_201609.pdf)

Figure 2

Age distribution of the women who were treated with assisted reproductive technology procedures in Japan in 2008. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2008 (https://plaza.umin.ac.jp/~jsog-art/2008data_pdf.pdf)

Figure 3

Number of cycles in each assisted reproductive technology procedure in Japan between 1992 and 2014. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2014 (https://plaza.umin.ac.jp/~jsog-art/2014data_201609.pdf). FET, frozen–thawed embryo transfer; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization

Figure 4

Number of live births after assisted reproductive technology procedures in Japan between 1992 and 2014. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2014 (https://plaza.umin.ac.jp/~jsog-art/2014data_201609.pdf). FET, frozen–thawed embryo transfer; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization

Age distribution of the women who were treated with assisted reproductive technology procedures in Japan in 2014. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2014 (https://plaza.umin.ac.jp/~jsog-art/2014data_201609.pdf) Age distribution of the women who were treated with assisted reproductive technology procedures in Japan in 2008. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2008 (https://plaza.umin.ac.jp/~jsog-art/2008data_pdf.pdf) Number of cycles in each assisted reproductive technology procedure in Japan between 1992 and 2014. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2014 (https://plaza.umin.ac.jp/~jsog-art/2014data_201609.pdf). FET, frozen–thawed embryo transfer; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization Number of live births after assisted reproductive technology procedures in Japan between 1992 and 2014. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2014 (https://plaza.umin.ac.jp/~jsog-art/2014data_201609.pdf). FET, frozen–thawed embryo transfer; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization Figure 5 shows the outcomes of ART by patient age for all treatment cycles. As the age increases, the success rate decreases and the rate of miscarriage increases. Compared to the 2008 results (Figure 6), these outcomes represent a slight increase, but no major change.
Figure 5

Rates of pregnancy, live birth, and miscarriage at each age in Japan in 2014. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2014 (https://plaza.umin.ac.jp/~jsog-art/2014data_201609.pdf). ET, embryo transfer

Figure 6

Rates of pregnancy, live birth, and miscarriage at each age in Japan in 2008. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2008 (https://plaza.umin.ac.jp/~jsog-art/2008data_pdf.pdf). ET, embryo transfer

Rates of pregnancy, live birth, and miscarriage at each age in Japan in 2014. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2014 (https://plaza.umin.ac.jp/~jsog-art/2014data_201609.pdf). ET, embryo transfer Rates of pregnancy, live birth, and miscarriage at each age in Japan in 2008. Adapted from Japan Society of Obstetrics and Gynecology ART Databook 2008 (https://plaza.umin.ac.jp/~jsog-art/2008data_pdf.pdf). ET, embryo transfer

Conflict of Interest

There is no conflict of interest regarding the publication of this study.

Human Rights Statement and Informed Consent

All the procedures that were followed were in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments. Informed consent was obtained from all the patients in the study.

Animal rights

This article does not contain any study that was performed by any of the authors that included animal participants.
  1 in total

1.  Assisted reproductive technology in Japan: a summary report of 1992-2014 by the Ethics Committee, Japan Society of Obstetrics and Gynecology.

Authors:  Minoru Irahara; Akira Kuwahara; Takeshi Iwasa; Tomonori Ishikawa; Osamu Ishihara; Koji Kugu; Rintaro Sawa; Kouji Banno; Hidekazu Saito
Journal:  Reprod Med Biol       Date:  2017-04-18
  1 in total
  12 in total

1.  Creatine enhances the duration of sperm capacitation: a novel factor for improving in vitro fertilization with small numbers of sperm.

Authors:  Takashi Umehara; Tomoko Kawai; Masaaki Goto; JoAnne S Richards; Masayuki Shimada
Journal:  Hum Reprod       Date:  2018-06-01       Impact factor: 6.918

2.  Evaluation of transfer media containing different concentrations of hyaluronan for human in vitro fertilization.

Authors:  Takuji Nishihara; Yoshiharu Morimoto
Journal:  Reprod Med Biol       Date:  2017-08-18

3.  Assisted reproductive technology in Japan: a summary report of 1992-2014 by the Ethics Committee, Japan Society of Obstetrics and Gynecology.

Authors:  Minoru Irahara; Akira Kuwahara; Takeshi Iwasa; Tomonori Ishikawa; Osamu Ishihara; Koji Kugu; Rintaro Sawa; Kouji Banno; Hidekazu Saito
Journal:  Reprod Med Biol       Date:  2017-04-18

4.  ART Registries-Characteristics and experiences: A comparative study.

Authors:  Maryam Zahmatkeshan; Majid Naghdi; Mojtaba Farjam; Mehrshad Mokhtaran; Azita Yazdani; Zahra Mahmoudvand; Reza Safdari
Journal:  J Family Med Prim Care       Date:  2019-02

5.  Assisted reproductive technology in Japan: A summary report for 2016 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology.

Authors:  Osamu Ishihara; Seung Chik Jwa; Akira Kuwahara; Tomonori Ishikawa; Koji Kugu; Rintaro Sawa; Kouji Banno; Minoru Irahara; Hidekazu Saito
Journal:  Reprod Med Biol       Date:  2018-11-29

6.  Assisted reproductive technology in Japan: A summary report for 2018 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology.

Authors:  Osamu Ishihara; Seung Chik Jwa; Akira Kuwahara; Yukiko Katagiri; Yoshimitsu Kuwabara; Toshio Hamatani; Miyuki Harada; Yutaka Osuga
Journal:  Reprod Med Biol       Date:  2020-11-20

7.  Assisted reproductive technology in Japan: a summary report for 2015 by The Ethics Committee of The Japan Society of Obstetrics and Gynecology.

Authors:  Hidekazu Saito; Seung Chik Jwa; Akira Kuwahara; Kazuki Saito; Tomonori Ishikawa; Osamu Ishihara; Koji Kugu; Rintaro Sawa; Kouji Banno; Minoru Irahara
Journal:  Reprod Med Biol       Date:  2017-11-29

8.  Pilot study of the optimal protocol of low dose step-up follicle stimulating hormone therapy for infertile women.

Authors:  Toshiya Matsuzaki; Takeshi Iwasa; Rie Yanagihara; Mizuki Komasaka; Kiyohito Yano; Yiliyasi Mayila; Ayaka Tachibana; Yuri Yamamoto; Takeshi Kato; Akira Kuwahara; Minoru Irahara
Journal:  Reprod Med Biol       Date:  2018-06-12

9.  Assisted reproductive technology in Japan: A summary report for 2017 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology.

Authors:  Osamu Ishihara; Seung Chik Jwa; Akira Kuwahara; Yukiko Katagiri; Yoshimitsu Kuwabara; Toshio Hamatani; Miyuki Harada; Tomohiko Ichikawa
Journal:  Reprod Med Biol       Date:  2019-11-21

10.  Lack of a meaningful association between dietary patterns and in vitro fertilization outcome among Japanese women.

Authors:  Miki Sugawa; Hitomi Okubo; Satoshi Sasaki; Yuko Nakagawa; Tamotsu Kobayashi; Keiichi Kato
Journal:  Reprod Med Biol       Date:  2018-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.